Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Treasury Shares (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Treasury Shares for 3 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 421.07% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 421.07% increase, with the full-year FY2025 number at $2.6 million, up 421.07% from a year prior.
  • Treasury Shares was $2.6 million for Q4 2025 at Artiva Biotherapeutics, up from $1.3 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.6 million in Q4 2025 to a low of $22514.0 in Q4 2023.
  • A 3-year average of $1.2 million and a median of $1.4 million in 2025 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 2151.24% in 2024, then skyrocketed 421.07% in 2025.
  • Artiva Biotherapeutics' Treasury Shares stood at $22514.0 in 2023, then soared by 2151.24% to $506845.0 in 2024, then surged by 421.07% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Treasury Shares are $2.6 million (Q4 2025), $1.3 million (Q3 2025), and $1.4 million (Q2 2025).